I think fears of abacavir hypersensitivity are vastly exagerated. People think physicians actively prefer Truvada over Epzicom, while I would argue that they are using it by inertia and if there is a really good clean highly effective integrase that does not need artifical boosting to be QD, I'd be ok using it with Epzicom instead of Truvada (after testing for abacavir hypersensitivity). As I said, it'll come down to who is a better marketer, GILD or ViiV - it'll be a very interesting fight to watch.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.